people with type 2 diabetes (12, 13) . Enhanced mitochondrial fission has also been reported in neurons from diabetic animal models (14) and in endothelium from individuals with type 2 diabetes (15) , and impaired expression of the fusion regulator mitofusin-2 was reported in diabetic muscle (16) . In b-cells, mitochondrial fission has been shown to contribute to apoptosis (17) as well as impaired insulin secretion (18) in the presence of hyperglycemia. Importantly, enhanced mitochondrial fission and fragmentation were demonstrated to be causally involved in ROS overproduction induced by hyperglycemia in liver and muscle cells (19) , thereby indicating a causal link between altered mitochondrial dynamics and diabetic oxidative stress.
In this issue of Diabetes, Galloway et al. (20) report the impact of the inhibition of mitochondrial fission through a negative mutant of its regulator dynamin-like protein 1 on mitochondrial bioenergetics and diabetic oxidative stress. In an in vitro model, inhibiting fission in hepatocytes caused mild proton leak across the mitochondrial membrane, i.e., the partial dissipation of mitochondrial membrane potential uncoupled from ATP synthase activity (20) . However, these effects were not associated with lower activity of electron transport chain components, or with relevant short-term impairment of ATP production capacity (20) . Since membrane hyperpolarization contributes to mitochondrial ROS overproduction in diabetes (5), the authors went on to test the hypothesis that impairment of mitochondrial fission through transgene expression of the same dynamin-like protein 1 mutant would lower ROS generation in a streptozotocin-induced diabetic rodent model. Under these conditions, the authors focused on kidney and liver and observed lower ROS production with low markers of oxidative stress in both tissues (20) . Importantly, improvements of the diabetic phenotype were reported in terms of apparent animal wellbeing and indexes of renal function (20) .
The relevance of the article by Galloway et al. is twofold. First, the article provides novel insight on the role of fission in regulating both mitochondrial bioenergetics and function through changes in proton leak and membrane potential. Moreover, it demonstrates beneficial effects of inhibiting mitochondrial fission on oxidative stress and diabetic phenotype in vivo. The study therefore introduces fission as a potential target for treatment of diabetes-associated morbidity triggered by oxidative stress. The authors also recognize that the relevant role of mitochondrial dynamics in maintenance of cell and tissue homeostasis warrants extensive additional investigations on the long-term biological impact and safety of this approach before it may be considered for translation into clinical applications. Additional questions relate to the potential long-term consequences of enhanced uncoupling on mitochondrial function, and possibly on tissue and body energy balance. Moreover, mitochondria are not the only source of ROS involved in the pathogenesis of diabetes complications; the roles of NADPH oxidases, xanthine oxidase, and cyclooxygenase have been described in various tissues (2,3). The long-term impact of nonmitochondrial sources of oxidative stress could limit the beneficial impact of lower mitochondrial ROS production, an issue that will also need to be elucidated.
With the above considerations in mind, the findings of the study by Galloway et al. strengthen the rationale for research on mitochondrial dynamics and its alterations in diabetes, and suggest that the sites of common diabetes complications may be logical targets for future investigation. Further studies are also supported in pancreatic b-cells, skeletal muscle, and liver, where altered mitochondrial morphology and function are associated with, and may be causally linked to, impaired insulin secretion, altered lipid metabolism, and insulin resistance (2, 17, 18, 21, 22) . From a molecular standpoint, the mediators linking changes in mitochondrial dynamics to changes in proton leak and membrane potential also need to be identified and will potentially become key intervention targets. Addressing these issues will likely result in useful information on the pathophysiological role of mitochondrial dynamics in diabetes and diabetes complications that could eventually lead to innovative and effective therapeutic approaches. 
